Stockreport
Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board [Yahoo! Finance]
Last edwards lifesciences corporation earnings: 4/23 04:15 pm
Check Earnings Report
US:NYSE Investor Relations: ir.edwards.com
implant designed to intelligently monitor and modulate cardiac preload to relieve congestion in heart failure, today announced the appointment of Harry Rowland as Chairman of the Board. Harry Rowland served as the chief executive officer of Endotronix, a medical device company he co-founded that developed the Cordella™ Pulmonary Artery (PA) Sensor System. Under his leadership, Endotronix advanced the technology through pivotal study completion, commercial approval, and ultimately its acquisition by Edwards Lifesciences in 2024. "Harry is a remarkable leader who guided Endotronix from napkin sketch to commercial approval and exit," said Alex Cooper, Chief Executive Officer of Relief Cardiovascular. "His leadership experience, domain expertise, and understanding of the clinical and operational complexities of remote management make him an exceptional fit for Relief as we expand the Relief System into broader clinical evaluation. I'm excited to work alongside Harry – his guidance wil
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EW | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EW alerts
EW alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EW alerts
High impacting Edwards Lifesciences Corporation news events
Weekly update
A roundup of the hottest topics
EW
NEWS
NEWS
- Edwards Lifesciences (NYSE:EW) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $90.00.[MarketBeat]
- Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Wells Fargo & Company.[MarketBeat]
- Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference[Business Wire]
- Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider [Yahoo! Finance][Yahoo! Finance]
- Edwards Lifesciences (NYSE:EW) was given a new $87.00 price target on by analysts at Canaccord Genuity Group Inc..[MarketBeat]
- More
EW
SEC Filings
SEC Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- EW's page on the SEC website
- More